StockNews.AI
TMDX
StockNews.AI
187 days

TransMedics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

1. TransMedics will release Q4 and 2024 financial results on February 27, 2025. 2. A conference call will follow the results release to discuss details. 3. TransMedics leads in preserving donor organs for transplantation technology. 4. Their technologies improve organ quality and increase donor organ utilization.

4m saved
Insight
Article

FAQ

Why Neutral?

The scheduled earnings call may provide clarity but isn't expected to significantly impact stock prices, similar to previous earnings announcements.

How important is it?

The earnings report and call are relatively important for investor insight but do not indicate major upcoming changes.

Why Short Term?

The upcoming earnings report will have short-term market reactions based on performance metrics.

Related Companies

TMDX
, /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2024 after market close on Thursday, February 27, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 481-2832 for domestic callers or (412) 317-1852 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.    About TransMedics Group, Inc.TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Investor Contact:Brian JohnstonLaine Morgan332-895-3222[email protected] SOURCE TransMedics Group, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News